NTRK1 and glioblastoma: Due to glioblastoma cell heterogeneity and genetic instability, clinical trials for targeted therapies (e.g., therapies targeting receptor tyrosine kinase signaling) have also failed to improve glioblastoma patient outcomes8,9.